ArticleJournal for immunotherapy of cancer2022

CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer.

Weilin Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.